GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
Adriano Venditti(University of Rome Tor Vergata), Sergio Amadori(University of Rome Tor Vergata), Francesco Buccisano(University of Rome Tor Vergata), Anna Candoni(University of Udine), Maria Antonietta Irno-Consalvo(University of Rome Tor Vergata), Mario Luppi(University of Modena and Reggio Emilia), Alessia Tieghi(Azienda Sanitaria Unità Locale di Reggio Emilia), Robin Foà(Institute of Oncology Research), Nicola Fracchiolla(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Paola Fazi(San Antonio College), Francesco Lanza(Ospedale "Santa Maria delle Croci" di Ravenna), Roberto Cairoli(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Luca Maurillo(University of Rome Tor Vergata), Lorella Melillo(San Antonio College), Edoardo La Sala(Fondazione Gimema Onlus), Alfonso Piciocchi(Fondazione Gimema Onlus), Maria Ilaria Del Principe(University of Rome Tor Vergata), William Arcese(University of Rome Tor Vergata), Agostino Tafuri(Sapienza University of Rome), Antonio Cuneo(Arcispedale Sant'Anna), Debora Capelli(Ospedali Riuniti Umberto I), Francesco Lo‐Coco(University of Rome Tor Vergata), Serena Lavorgna(University of Rome Tor Vergata), Maria Teresa Voso(University of Rome Tor Vergata), Gabriella Storti(Azienda Ospedaliera S.Giuseppe Moscati), Tiziana Ottone(University of Rome Tor Vergata), Francesco Albano(Centro di Riferimento Oncologico della Basilicata), Giovanni Martinelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Marco Vignetti(San Antonio College), Anna Chierichini(Azienda Ospedaliera San Giovanni Addolorata), Prassede Salutari(Azienda USL di Pescara), Maria Paola Martelli(University of Perugia), Francesco Fabbiano(San Antonio College), Caterina Alati(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Patrizio Mazza(Ospedale SS. Annunziata), Paolo de Fabritiis(St. Eugenio Hospital), Valeria Calafiore(Ferrarotto Hospital)
Cited by 215
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k